Cancer research and treatment has evolved considerably over recent years, and one of the most promising modalities to emerge is immuno-oncology.
Arguably one of the greatest breakthroughs in modern medicine, immuno-oncology essentially unlocks the breaks on the body’s natural ability to attack and fight off cancer.
Immuno-oncology therapeutics help to reprogram the immune system so that it recognizes and destroys cancer cells, which under normal circumstances may be able to evade an immune system attack.
Pharmaceutical companies are pursuing several types of immuno-oncology products, including checkpoint inhibitors, tumor necrosis factor receptor agonists, adoptive T-cell therapies such as chimeric antigen receptor T-cell (CAR-T) technology, tumor-infiltrating lymphocytes, and vaccines.
As of July 2019, there are 25 immuno-oncology therapies (including monotherapies and combinations with chemotherapies or other products, but excluding biosimilars) launched throughout the world for a wide range of solid and hematological tumors.
Datamonitor Healthcare is part of Pharma intelligence
Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726